|
Press Releases |
|
|
|
Thursday, June 29, 2023 |
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun |
NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. more info >> |
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun |
NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. more info >> |
|
Wednesday, September 16, 2020 |
|
NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 |
NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program closer to human clinical trials. more info >> |
|
Wednesday, May 20, 2020 |
|
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus |
NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. more info >> |
|
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus |
NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. more info >> |
|
Tuesday, March 17, 2020 |
|
NanoViricides公司冠状病毒药物开发更新 |
NanoViricides公司(美国纽约证券交易所交易代码 NNVC)(公司)是基于新型纳米药学平台(公司)开发高效抗病毒治疗方法的领先公司,目前正在为造成COVID-19的当前新型冠状病毒SARS-CoV-2进行药物开发,现提供其工作相关更新。 more info >> |
|
NanoViricides公司冠狀病毒藥物開發更新 |
NanoViricides公司(美國紐約證券交易所交易代碼NNVC)(公司)是基於新型納米藥學平台(公司)開發高效抗病毒治療方法的領先公司,目前正在為造成COVID-19的當前新型冠狀病毒SARS-CoV-2進行藥物開發,現提供其工作相關更新。 more info >> |
|
NanoViricides社、新型コロナウイルス治療薬開発に関する最新情報を発表 |
新たなナノ医療プラットフォームを基盤に非常に効果的な抗ウイルス療法の開発でリードするNanoViricides社(NYSE American: NNVC) (以下「当社」)は、COVID-19を引き起こす現在の新型コロナウイルス(SARS-CoV-2)の治療薬開発に向けた取り組みについて最新情報を提供しています。 more info >> |
|
Monday, March 16, 2020 |
|
Coronavirus Drug Development Update from NanoViricides, Inc. |
NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. more info >> |
|
Coronavirus Drug Development Update from NanoViricides, Inc. |
NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Vinmec's Innovations Spotlighted at Global CSR & ESG Summit 2024
May 9, 2024 05:04 HKT/SGT
|
|
|
Formerra Achieves ISCC PLUS Certification Across U.S. Warehouses, Enhancing Sustainable Material Distribution
May 8, 2024 22:00 HKT/SGT
|
|
|
Build4Asia 及亞洲零售論壇暨博覽會今日開幕
May 8, 2024 21:29 HKT/SGT
|
|
|
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
May 8, 2024 21:10 HKT/SGT
|
|
|
Build4Asia and Retail Asia Conference & Expo Kick Off Today
May 8, 2024 21:10 HKT/SGT
|
|
|
国美金融科技宣布拟收购游戏公司CashBox Group
May 8, 2024 21:04 HKT/SGT
|
|
|
國美金融科技宣佈擬收購遊戲公司CashBox Group
May 8, 2024 21:00 HKT/SGT
|
|
|
Indonesian BFSI IT Summit: Revolutionizing Finance Through Digital Transformation
May 8, 2024 17:12 HKT/SGT
|
|
|
Crypto Oasis Thrives: UAE Blockchain Ecosystem sees Exponential Growth with 2,040 Active Organizations in Q1 2024
May 8, 2024 17:00 HKT/SGT
|
|
|
Datacloud APAC: Charting the Course for APAC's Cloud Future
May 8, 2024 16:20 HKT/SGT
|
|
|
アフリカがついに日本のビジネスにおける国境を開放
May 8, 2024 15:00: JST
|
|
|
以数智化殡葬直面变化与挑战 福寿园国际集团组团参加2024AFE亚洲殡仪及墓园博览暨会议
May 8, 2024 14:05 HKT/SGT
|
|
|
以數智化殯葬直面變化與挑戰 福壽園國際集團組團參加2024AFE亞洲殯儀及墓園博覽暨會議
May 8, 2024 14:01 HKT/SGT
|
|
|
Mitsubishi Heavy Industries Increases Dividends on Back of Historically High FY2023 Results, Releases FY2024 Guidance
May 8, 2024 14:27 JST
|
|
|
Capital.com 的客戶交易量在2023年超過了1萬億美元
May 8, 2024 12:18 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|